Cyclin-Dependent Kinase Inhibitor p27
"Cyclin-Dependent Kinase Inhibitor p27" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin-dependent kinase inhibitor that coordinates the activation of CYCLIN and CYCLIN-DEPENDENT KINASES during the CELL CYCLE. It interacts with active CYCLIN D complexed to CYCLIN-DEPENDENT KINASE 4 in proliferating cells, while in arrested cells it binds and inhibits CYCLIN E complexed to CYCLIN-DEPENDENT KINASE 2.
| Descriptor ID |
D050760
|
| MeSH Number(s) |
D12.644.360.225.600 D12.776.167.187.600 D12.776.476.225.600 D12.776.624.776.355.600
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p27- Cyclin-Dependent Kinase Inhibitor p27
- Cyclin Dependent Kinase Inhibitor p27
- CDKN4 Protein
- p27 CDK Inhibitor
- CDK Inhibitor, p27
- p27 Kip1 Protein
- Kip1 Protein, p27
- CDKN1B Protein
- p27Kip1 Protein
- CDK Inhibitor p27
- p27, CDK Inhibitor
- Cyclin-Dependent Kinase Inhibitor 1B
- Cyclin Dependent Kinase Inhibitor 1B
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p27".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p27".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p27" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p27" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p27" by people in Profiles.
-
HDAC1 overexpression enhances ?-cell proliferation by down-regulating Cdkn1b/p27. Biochem J. 2018 12 19; 475(24):3997-4010.
-
Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
-
Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.
-
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008 Jul 01; 10:e19.
-
Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope. 1999 Aug; 109(8):1329-33.